SMART MONEY GROUP

[Captain Hindsight]

$NBIO Insiders buying acquiring shares ahead of FDA, and clinical trial results.

5,600,000 float

http://archive.fast-edgar.com//20190606/AMZ2R22CZ22FA9N3222D2ZZ2QR5VPZ27Z2B2/

Nascent Executive Vice President of Business Development Brandon Price stated, “My strong belief in the Company, and the clinical value of our Pritumumab treatment for brain cancer, compel me to further take a position in its future and help advance our asset.”

Nascent CFO Lowell Holden stated, “I believe the Company has continued to be undervalued and is now positioned to add significant value. The IND clearance by the FDA, along with the pending commencement of clinical trials, gives me confidence in its growth.

Nascent CEO Sean Carrick added, “The confidence in the Company by the management team, with their dedication and financial support, should positively impact our shareholders and the market as we continue our effort to monetize Nascent’s assets.”